SHL FINANCIAL STATEMENTS

Sonic Healthcare Ltd — balance sheet, income statement and cash flow trends

SHLSonic Healthcare Ltd

🇦🇺 Australia · AU · Healthcare · Diagnostics & Research

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q2 2025 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue10.4 B A$+26.5%

Gross Profit3.1 B A$+51.1%

Operating Income2 B A$+216.0%

EBITDA1.8 B A$+62.4%

Net Income539.4 M A$+6.8%

Peer Comparison· Diagnostics & Research

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
SHL	11.4%	29.6%	17.3%	5.2%
QGEN	4.8%	61.6%	37.1%	19.2%
TWST	17.8%	52.1%	-13.8%	-19.8%
RDNT	14.7%	9.4%	15.1%	-0.7%
SHC	7.4%	55.0%	41.1%	9.9%
CRL	0.1%	31.9%	7.2%	-4.6%
Industry median	9.1%	53.0%	18.8%	6.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
SHL	11.4%	29.6%	17.3%	5.2%
RHC	8.6%	10.6%	8.9%	1.6%
COH	2.0%	73.0%	24.0%	14.6%
FPH	4.8%	64.2%	34.9%	20.0%
PME	30.3%	78.4%	78.4%	97.6%
TLX	56.3%	50.8%	3.0%	-0.9%
Industry median	9.1%	53.0%	18.8%	6.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q2 2025

Equity8.6 B A$51%
Current Liabilities2.5 B A$15%
Long-term Liabilities5.8 B A$34%

Key Figures

YoY change

Total Assets17 B A$+23.7%

Total Liabilities8.3 B A$+41.6%

Total Equity8.6 B A$+11.0%

Cash & ST Investments557.1 M A$-10.1%

Total Debt7.3 B A$+84.1%

Net Debt7.3 B A$+117.9%

Peer Comparison· Diagnostics & Research

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
SHL	1.01	85.8%	3.78	50.3%
QGEN	3.21	49.4%	1.29	57.6%
TWST	2.70	21.1%	1.35	67.3%
RDNT	1.17	179.0%	4.56	27.8%
SHC	2.82	364.7%	4.00	19.2%
CRL	1.36	103.9%	9.86	38.0%
Industry median	1.87	49.3%	1.92	50.1%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
SHL	1.01	85.8%	3.78	50.3%
RHC	0.90	347.6%	10.29	23.3%
COH	2.46	22.1%	0.42	69.4%
FPH	2.31	6.9%	-0.39	74.1%
PME	6.22	1.1%	-1.16	72.8%
TLX	1.43	112.3%	13.13	35.1%
Industry median	1.87	49.3%	1.92	50.1%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q2 2025 · TTM

Key Figures

YoY change

Operating Cash Flow1.4 B A$+71.0%

Capital Expenditures492.8 M A$+22.9%

Free Cash Flow866 M A$+119.8%

Dividends Paid-522.7 M A$-233.2%

Peer Comparison· Diagnostics & Research

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
SHL	13.1%	8.3%	4.7%	251.9%
QGEN	29.3%	19.6%	9.8%	153.0%
TWST	-13.6%	-23.2%	9.7%	68.4%
RDNT	16.3%	-6.9%	23.2%	-2,463.4%
SHC	22.0%	8.1%	13.8%	221.7%
CRL	15.1%	9.7%	5.4%	-328.7%
Industry median	16.3%	9.7%	4.5%	110.1%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
SHL	13.1%	8.3%	4.7%	251.9%
RHC	8.3%	3.9%	4.4%	531.1%
COH	11.2%	8.5%	2.7%	76.6%
FPH	28.4%	21.0%	7.4%	141.7%
PME	56.5%	56.3%	0.2%	57.9%
TLX	-2.2%	-6.3%	4.1%	243.1%
Industry median	16.3%	9.7%	4.5%	110.1%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on SHL

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.